Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Rs-1"

270 News Found

Aurobindo enters domestic formulations space with the acquisition of Veritaz for Rs 171 Cr
News | March 28, 2022

Aurobindo enters domestic formulations space with the acquisition of Veritaz for Rs 171 Cr

Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments


Venus Remedies aims to achieve Rs 1000 crore turnover by 2025: Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre
interviews | March 22, 2022

Venus Remedies aims to achieve Rs 1000 crore turnover by 2025: Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre

Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025


IOL Chemicals and Pharmaceuticals to limit capex at Rs 150 crore per year
News | March 07, 2022

IOL Chemicals and Pharmaceuticals to limit capex at Rs 150 crore per year

The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business


Govt announces over Rs 100 crore investment for Ayush sector in Nagaland
Public Health | March 04, 2022

Govt announces over Rs 100 crore investment for Ayush sector in Nagaland

Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram


Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
News | February 28, 2022

Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr

Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business


Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.
Policy | February 27, 2022

Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.

Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked


Granules India Q3FY22 PAT at Rs 100.88 cr.
News | February 08, 2022

Granules India Q3FY22 PAT at Rs 100.88 cr.

Granules India has reported consolidated financial results for the period ended December 31, 2021


AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.
News | February 08, 2022

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.

Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021


Pfizer Q3FY22 PAT at Rs 143.91 crore
News | February 04, 2022

Pfizer Q3FY22 PAT at Rs 143.91 crore

The company has reported standalone financial results for the period ended December 31, 2021.


Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021